Wellcome Leap logo
CARE

CARE — Execution

Supports United Kingdom efforts to understand endocrine factors in cognitive aging and dementia risk.

ClosedWellcome Leap
View on funder site
About

CARE — Cutting Alzheimer's Risk through Endocrinology — is a Wellcome Leap program within the organization's $50 million Women's Health initiative, targeting a reduction in women's lifetime risk of Alzheimer's disease through endocrine mechanisms. The program's stated ambition is to cut that risk in half by 2050, which Wellcome Leap estimates could prevent approximately 54.5 million cases of Alzhe…

What this grant funds

Reducing women's lifetime risk of Alzheimer's disease through endocrinology, targeting biomarker development, neuroimaging, and predictive modeling to prevent an estimated 54.5 million cases globally.

Key facts
CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.One-off
Next deadlineiThe next date applications are due. Rolling means you can apply any time.—
Decision timeiTypical time from the deadline to the funder's decision.—
Project durationiHow long the funded work is expected to run.—
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Cooperative agreement
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.0%
Funding pooliThe total budget available across all awards in this round.$50M
Funding analytics

Sign up free to see the funding breakdown

Create free accountSign in
Industries

Sign up free to see the industries in scope

Create free accountSign in
Eligibility criteria

Sign up free to see the full eligibility

Create free accountSign in
Last verified: 22 Jul 2026Source: wellcomeleap.org